A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina

Health Technology Assessment

Volumn 4, Issue 30, 2000, Pages

  McDonagh, M S ^a   Bachmann, L M ^a   Golder, S ^a   Kleijnen, J ^a   Ter Riet, G ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; LEFRADAFIBAN; NITRATE; ORBOFIBAN; SIBRAFIBAN; TIROFIBAN; TROPONIN I; TROPONIN T;

BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE MARKER; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATALITY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; PROTEIN BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STROKE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034521725     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta4300     Document Type: Review

References (46)

1. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: A 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden
2. A new clinical classification for hospital prognosis of unstable angina pectoris
3. Nifedipine and conventional therapy for unstable angina pectoris: A randomised, double-blind comparison
4. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group
5. Risk of adverse outcome in patients admitted to the coronary care unit with suspected unstable angina pectoris
6. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people
7. Reactivation of unstable angina after the discontinuation of heparin
8. A randomised study comparing propranolol and diltiazem in the treatment of unstable angina
9. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
10. Comparison of the natural history of new onset and exacerbated chronic ischemic heart disease
11. One-year prognosis in patients hospitalized with a history of unstable angina pectoris
12. Incidence, clinical characteristics, and short-term prognosis of angina pectoris
13. The epidemiology of unstable angina
14. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
15. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
16. Effects of integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomised multicenter trial
17. Design and methodology of the PURSUIT trial: Evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
18. PURSUIT (Platelet IIb/IIIa in unstable angina: Receptor suppression using Integrilin™ therapy)
19. New findings from the PURSUIT study
20. Stroke in patients with acute coronary syndromes: Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators
21. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
22. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study
23. International, randomised, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a Global Organization Network
24. Optimal dosing of a platelet glycoprotein IIb/IIIa antagonist, lamifiban, using renal-based algorithms, in patients with acute coronary syndromes: Results from the PARAGON B (the Platelet IIb/IIIa antagonist for the reduction of acute coronary syndrome events in a global organization network) study
25. Thrombolysis in myocardial infarction (TIMI) trial, phase I
26. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction
27. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischemic Heart events post-acute coronary syndromes
28. A randomised comparison of sibrafiban, an oral glycoprotein (GP) IIb/IIIa receptor antagonist, with and without aspirin vs. aspirin after acute coronary syndromes: Results of the second SYMPHONY trial
29. Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology
30. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial
31. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting. An analysis based on the PRISM-PLUS trial
32. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
33. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes
34. Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes
35. Economic issues in glycoprotein IIb/IIIa receptor therapy
36. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK)
37. Randomised trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction
38. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease